Stem definition | Drug id | CAS RN |
---|---|---|
antihypertensives, hydrazinephthalazine derivatives | 1384 | 86-54-4 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 44.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 8 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 20.79 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 23 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.50 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 85 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.12 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 15, 1953 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anti-neutrophil cytoplasmic antibody positive vasculitis | 1070.66 | 11.66 | 241 | 25157 | 1694 | 46658970 |
Glomerulonephritis rapidly progressive | 368.50 | 11.66 | 84 | 25314 | 627 | 46660037 |
Pulmonary renal syndrome | 295.66 | 11.66 | 63 | 25335 | 329 | 46660335 |
Cardiac failure congestive | 294.62 | 11.66 | 303 | 25095 | 91447 | 46569217 |
Gastrointestinal tract mucosal pigmentation | 224.07 | 11.66 | 54 | 25344 | 526 | 46660138 |
Glomerulonephritis | 166.59 | 11.66 | 53 | 25345 | 1520 | 46659144 |
Lupus-like syndrome | 153.02 | 11.66 | 78 | 25320 | 7766 | 46652898 |
Hypertension | 138.82 | 11.66 | 320 | 25078 | 196036 | 46464628 |
Exposure during pregnancy | 126.77 | 11.66 | 218 | 25180 | 107994 | 46552670 |
Acute kidney injury | 115.65 | 11.66 | 335 | 25063 | 235520 | 46425144 |
Vasculitis | 105.65 | 11.66 | 75 | 25323 | 13636 | 46647028 |
Rheumatoid arthritis | 95.27 | 11.66 | 10 | 25388 | 240205 | 46420459 |
Renal vasculitis | 90.84 | 11.66 | 22 | 25376 | 219 | 46660445 |
Pulmonary alveolar haemorrhage | 88.85 | 11.66 | 44 | 25354 | 4118 | 46656546 |
Pre-eclampsia | 83.92 | 11.66 | 53 | 25345 | 7941 | 46652723 |
Glomerulonephritis proliferative | 80.58 | 11.66 | 19 | 25379 | 167 | 46660497 |
Chronic kidney disease | 80.36 | 11.66 | 105 | 25293 | 40766 | 46619898 |
Blood pressure inadequately controlled | 72.21 | 11.66 | 39 | 25359 | 4367 | 46656297 |
Premature delivery | 69.05 | 11.66 | 72 | 25326 | 21997 | 46638667 |
Cerebrovascular accident | 62.95 | 11.66 | 157 | 25241 | 100882 | 46559782 |
Lupus nephritis | 57.81 | 11.66 | 27 | 25371 | 2219 | 46658445 |
Low birth weight baby | 52.02 | 11.66 | 34 | 25364 | 5400 | 46655264 |
Hyperkalaemia | 51.39 | 11.66 | 96 | 25302 | 50613 | 46610051 |
Pulmonary oedema | 50.86 | 11.66 | 96 | 25302 | 51009 | 46609655 |
Fluid overload | 50.59 | 11.66 | 68 | 25330 | 27117 | 46633547 |
End stage renal disease | 49.55 | 11.66 | 34 | 25364 | 5852 | 46654812 |
Loss of employment | 48.22 | 11.66 | 20 | 25378 | 1236 | 46659428 |
Renal failure | 47.67 | 11.66 | 153 | 25245 | 113441 | 46547223 |
Antineutrophil cytoplasmic antibody positive | 45.97 | 11.66 | 15 | 25383 | 467 | 46660197 |
Mental status changes | 44.86 | 11.66 | 77 | 25321 | 38011 | 46622653 |
BRASH syndrome | 41.62 | 11.66 | 10 | 25388 | 96 | 46660568 |
Premature baby | 41.10 | 11.66 | 50 | 25348 | 18062 | 46642602 |
Premature labour | 39.23 | 11.66 | 39 | 25359 | 11260 | 46649404 |
Alveolitis | 37.74 | 11.66 | 21 | 25377 | 2492 | 46658172 |
Generalised oedema | 36.39 | 11.66 | 42 | 25356 | 14357 | 46646307 |
Blood pressure increased | 35.72 | 11.66 | 150 | 25248 | 126516 | 46534148 |
Dyspnoea | 34.23 | 11.66 | 429 | 24969 | 515119 | 46145545 |
Norepinephrine increased | 33.76 | 11.66 | 8 | 25390 | 72 | 46660592 |
Maternal exposure during pregnancy | 33.36 | 11.66 | 127 | 25271 | 102422 | 46558242 |
Hospitalisation | 30.89 | 11.66 | 90 | 25308 | 63295 | 46597369 |
Hypoxia | 30.63 | 11.66 | 79 | 25319 | 51759 | 46608905 |
Blood glucose decreased | 30.29 | 11.66 | 44 | 25354 | 18848 | 46641816 |
Peritonitis bacterial | 30.28 | 11.66 | 30 | 25368 | 8623 | 46652041 |
Nephrogenic systemic fibrosis | 29.78 | 11.66 | 23 | 25375 | 4749 | 46655915 |
Shock | 29.53 | 11.66 | 47 | 25351 | 21798 | 46638866 |
Atrial fibrillation | 29.45 | 11.66 | 123 | 25275 | 103467 | 46557197 |
Acute febrile neutrophilic dermatosis | 28.67 | 11.66 | 18 | 25380 | 2667 | 46657997 |
Treatment failure | 27.91 | 11.66 | 8 | 25390 | 93079 | 46567585 |
Respiratory failure | 27.27 | 11.66 | 113 | 25285 | 94703 | 46565961 |
Gastrointestinal haemorrhage | 26.97 | 11.66 | 98 | 25300 | 77275 | 46583389 |
Myocardial infarction | 26.32 | 11.66 | 114 | 25284 | 97414 | 46563250 |
Diabetes mellitus inadequate control | 26.03 | 11.66 | 34 | 25364 | 13180 | 46647484 |
Vasculitis necrotising | 25.20 | 11.66 | 10 | 25388 | 551 | 46660113 |
Joint swelling | 24.18 | 11.66 | 33 | 25365 | 166040 | 46494624 |
HELLP syndrome | 23.43 | 11.66 | 11 | 25387 | 915 | 46659749 |
Alopecia | 22.92 | 11.66 | 33 | 25365 | 162381 | 46498283 |
Oedema peripheral | 22.88 | 11.66 | 157 | 25241 | 159549 | 46501115 |
Endometritis | 22.84 | 11.66 | 11 | 25387 | 968 | 46659696 |
Eclampsia | 22.53 | 11.66 | 8 | 25390 | 323 | 46660341 |
Off label use | 22.12 | 11.66 | 119 | 25279 | 379722 | 46280942 |
Nodal rhythm | 22.11 | 11.66 | 13 | 25385 | 1712 | 46658952 |
Drug abuse | 21.90 | 11.66 | 4 | 25394 | 63404 | 46597260 |
Pulseless electrical activity | 21.73 | 11.66 | 23 | 25375 | 7144 | 46653520 |
Orthopnoea | 21.72 | 11.66 | 21 | 25377 | 5859 | 46654805 |
Pleural effusion | 21.65 | 11.66 | 96 | 25302 | 82856 | 46577808 |
Neutropenia | 21.30 | 11.66 | 28 | 25370 | 143176 | 46517488 |
Hypotension | 21.06 | 11.66 | 206 | 25192 | 232383 | 46428281 |
Peripartum cardiomyopathy | 20.85 | 11.66 | 6 | 25392 | 121 | 46660543 |
Multiple drug therapy | 20.54 | 11.66 | 10 | 25388 | 901 | 46659763 |
Hypermagnesaemia | 20.43 | 11.66 | 10 | 25388 | 912 | 46659752 |
Acute myocardial infarction | 20.26 | 11.66 | 50 | 25348 | 31874 | 46628790 |
Caesarean section | 20.11 | 11.66 | 34 | 25364 | 16569 | 46644095 |
Pyrexia | 19.90 | 11.66 | 110 | 25288 | 348692 | 46311972 |
Pernicious anaemia | 19.86 | 11.66 | 9 | 25389 | 690 | 46659974 |
Sinusitis | 19.69 | 11.66 | 25 | 25373 | 129743 | 46530921 |
Drug ineffective | 19.58 | 11.66 | 256 | 25142 | 677582 | 45983082 |
Hypoperfusion | 19.16 | 11.66 | 11 | 25387 | 1386 | 46659278 |
Renal impairment | 18.60 | 11.66 | 85 | 25313 | 74287 | 46586377 |
Bradycardia | 18.27 | 11.66 | 78 | 25320 | 66220 | 46594444 |
Cutaneous vasculitis | 18.13 | 11.66 | 16 | 25382 | 3975 | 46656689 |
Electrocardiogram QRS complex shortened | 17.83 | 11.66 | 7 | 25391 | 375 | 46660289 |
Hyperplasia adrenal | 17.77 | 11.66 | 4 | 25394 | 28 | 46660636 |
Haemolytic uraemic syndrome | 17.64 | 11.66 | 13 | 25385 | 2501 | 46658163 |
Haemodynamic instability | 16.99 | 11.66 | 21 | 25377 | 7704 | 46652960 |
Dialysis | 16.86 | 11.66 | 24 | 25374 | 10092 | 46650572 |
Psoriasis | 16.85 | 11.66 | 11 | 25387 | 78593 | 46582071 |
Injection site reaction | 16.56 | 11.66 | 3 | 25395 | 47846 | 46612818 |
Stillbirth | 16.51 | 11.66 | 19 | 25379 | 6472 | 46654192 |
Pain | 16.49 | 11.66 | 173 | 25225 | 476775 | 46183889 |
Foetal death | 16.46 | 11.66 | 22 | 25376 | 8721 | 46651943 |
Phaeochromocytoma | 16.45 | 11.66 | 7 | 25391 | 461 | 46660203 |
Proteinuria | 16.34 | 11.66 | 31 | 25367 | 16522 | 46644142 |
Blood creatinine increased | 16.00 | 11.66 | 83 | 25315 | 76320 | 46584344 |
Autoantibody positive | 15.99 | 11.66 | 4 | 25394 | 46 | 46660618 |
Musculoskeletal stiffness | 15.79 | 11.66 | 18 | 25380 | 97975 | 46562689 |
Neonatal hyponatraemia | 15.40 | 11.66 | 4 | 25394 | 54 | 46660610 |
Small for dates baby | 15.38 | 11.66 | 14 | 25384 | 3623 | 46657041 |
Therapeutic product effect incomplete | 15.36 | 11.66 | 12 | 25386 | 78141 | 46582523 |
Primary hyperaldosteronism | 15.33 | 11.66 | 4 | 25394 | 55 | 46660609 |
Hypertensive emergency | 15.18 | 11.66 | 10 | 25388 | 1608 | 46659056 |
Depression | 15.14 | 11.66 | 45 | 25353 | 170059 | 46490605 |
Jugular vein distension | 15.04 | 11.66 | 8 | 25390 | 868 | 46659796 |
Lupus pneumonitis | 15.01 | 11.66 | 4 | 25394 | 60 | 46660604 |
Death | 14.98 | 11.66 | 261 | 25137 | 335287 | 46325377 |
Inflammation | 14.98 | 11.66 | 4 | 25394 | 48777 | 46611887 |
Suicidal ideation | 14.90 | 11.66 | 6 | 25392 | 56376 | 46604288 |
Infusion related reaction | 14.83 | 11.66 | 20 | 25378 | 101188 | 46559476 |
Cortisol increased | 14.78 | 11.66 | 6 | 25392 | 351 | 46660313 |
Serositis | 14.63 | 11.66 | 7 | 25391 | 607 | 46660057 |
Phaeochromocytoma crisis | 14.55 | 11.66 | 5 | 25393 | 183 | 46660481 |
Abortion spontaneous | 14.55 | 11.66 | 3 | 25395 | 43643 | 46617021 |
Exercise tolerance decreased | 14.43 | 11.66 | 15 | 25383 | 4562 | 46656102 |
C3 glomerulopathy | 14.18 | 11.66 | 3 | 25395 | 15 | 46660649 |
Dermatitis bullous | 14.03 | 11.66 | 19 | 25379 | 7624 | 46653040 |
Injection site erythema | 13.91 | 11.66 | 12 | 25386 | 74415 | 46586249 |
Skin induration | 13.67 | 11.66 | 12 | 25386 | 2962 | 46657702 |
Hepatic steatosis | 13.54 | 11.66 | 36 | 25362 | 24006 | 46636658 |
Left ventricular hypertrophy | 13.43 | 11.66 | 15 | 25383 | 4948 | 46655716 |
Cardiac failure acute | 13.22 | 11.66 | 19 | 25379 | 8059 | 46652605 |
Arthropathy | 13.17 | 11.66 | 16 | 25382 | 84684 | 46575980 |
General physical health deterioration | 13.14 | 11.66 | 27 | 25371 | 115742 | 46544922 |
Foetal growth restriction | 13.10 | 11.66 | 17 | 25381 | 6550 | 46654114 |
Cardiac arrest | 13.00 | 11.66 | 89 | 25309 | 90310 | 46570354 |
Glossodynia | 12.96 | 11.66 | 4 | 25394 | 44369 | 46616295 |
Haemorrhagic transformation stroke | 12.89 | 11.66 | 8 | 25390 | 1162 | 46659502 |
Pulmonary hypertension | 12.88 | 11.66 | 46 | 25352 | 35947 | 46624717 |
C-reactive protein increased | 12.83 | 11.66 | 8 | 25390 | 58582 | 46602082 |
Lower respiratory tract infection | 12.80 | 11.66 | 7 | 25391 | 55082 | 46605582 |
Umbilical cord vascular disorder | 12.66 | 11.66 | 4 | 25394 | 112 | 46660552 |
Bone marrow oedema | 12.55 | 11.66 | 7 | 25391 | 834 | 46659830 |
Contusion | 12.50 | 11.66 | 86 | 25312 | 87401 | 46573263 |
Synovitis | 12.48 | 11.66 | 9 | 25389 | 61066 | 46599598 |
Respiratory distress | 12.48 | 11.66 | 42 | 25356 | 31874 | 46628790 |
Bicuspid aortic valve | 12.40 | 11.66 | 4 | 25394 | 120 | 46660544 |
Renal disorder | 12.14 | 11.66 | 37 | 25361 | 26649 | 46634015 |
Kidney transplant rejection | 12.10 | 11.66 | 13 | 25385 | 4105 | 46656559 |
Glomerulonephritis membranous | 12.08 | 11.66 | 6 | 25392 | 565 | 46660099 |
Hypertensive urgency | 11.92 | 11.66 | 4 | 25394 | 136 | 46660528 |
Sinus arrhythmia | 11.79 | 11.66 | 8 | 25390 | 1352 | 46659312 |
Cardiomegaly | 11.75 | 11.66 | 28 | 25370 | 17454 | 46643210 |
Lethargy | 11.70 | 11.66 | 57 | 25341 | 51114 | 46609550 |
Pulmonary haemorrhage | 11.68 | 11.66 | 16 | 25382 | 6489 | 46654175 |
Stag horn calculus | 11.68 | 11.66 | 4 | 25394 | 145 | 46660519 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anti-neutrophil cytoplasmic antibody positive vasculitis | 648.70 | 12.27 | 136 | 20397 | 487 | 29931458 |
Cardiac failure congestive | 269.76 | 12.27 | 310 | 20223 | 84097 | 29847848 |
Glomerulonephritis rapidly progressive | 226.26 | 12.27 | 54 | 20479 | 388 | 29931557 |
Lupus-like syndrome | 194.79 | 12.27 | 68 | 20465 | 2061 | 29929884 |
Pulmonary renal syndrome | 158.34 | 12.27 | 34 | 20499 | 140 | 29931805 |
Gastrointestinal tract mucosal pigmentation | 126.12 | 12.27 | 30 | 20503 | 212 | 29931733 |
Chronic kidney disease | 77.95 | 12.27 | 112 | 20421 | 37726 | 29894219 |
Acute kidney injury | 75.90 | 12.27 | 379 | 20154 | 273463 | 29658482 |
Hypertension | 67.11 | 12.27 | 209 | 20324 | 121145 | 29810800 |
Vasculitis | 66.10 | 12.27 | 50 | 20483 | 7940 | 29924005 |
Device interaction | 64.74 | 12.27 | 20 | 20513 | 408 | 29931537 |
Glomerulonephritis | 57.38 | 12.27 | 27 | 20506 | 1786 | 29930159 |
Renal vasculitis | 53.34 | 12.27 | 13 | 20520 | 103 | 29931842 |
Pulmonary alveolar haemorrhage | 49.66 | 12.27 | 39 | 20494 | 6542 | 29925403 |
Lupus nephritis | 46.50 | 12.27 | 14 | 20519 | 261 | 29931684 |
Systemic lupus erythematosus | 45.90 | 12.27 | 26 | 20507 | 2530 | 29929415 |
End stage renal disease | 45.49 | 12.27 | 39 | 20494 | 7396 | 29924549 |
Pulmonary oedema | 43.15 | 12.27 | 94 | 20439 | 43881 | 29888064 |
Renal failure | 38.03 | 12.27 | 182 | 20351 | 128784 | 29803161 |
Lupus vasculitis | 37.72 | 12.27 | 6 | 20527 | 0 | 29931945 |
Mental status changes | 37.22 | 12.27 | 80 | 20453 | 36999 | 29894946 |
Drug abuse | 36.89 | 12.27 | 6 | 20527 | 82066 | 29849879 |
Hypotension | 34.31 | 12.27 | 245 | 20288 | 200320 | 29731625 |
Myocardial infarction | 33.98 | 12.27 | 173 | 20360 | 125452 | 29806493 |
Apgar score low | 33.73 | 12.27 | 15 | 20518 | 870 | 29931075 |
Low birth weight baby | 31.46 | 12.27 | 29 | 20504 | 6047 | 29925898 |
Premature baby | 30.88 | 12.27 | 47 | 20486 | 16644 | 29915301 |
Drug ineffective | 26.97 | 12.27 | 131 | 20402 | 340256 | 29591689 |
Histone antibody positive | 25.62 | 12.27 | 5 | 20528 | 11 | 29931934 |
Unresponsive to stimuli | 24.24 | 12.27 | 55 | 20478 | 26364 | 29905581 |
Human ehrlichiosis | 24.14 | 12.27 | 8 | 20525 | 206 | 29931739 |
Lupus pneumonitis | 24.04 | 12.27 | 6 | 20527 | 53 | 29931892 |
Cerebrovascular accident | 23.28 | 12.27 | 116 | 20417 | 83361 | 29848584 |
Pyrexia | 22.92 | 12.27 | 114 | 20419 | 294375 | 29637570 |
Proteinuria | 22.48 | 12.27 | 40 | 20493 | 16105 | 29915840 |
Blood pressure increased | 21.52 | 12.27 | 102 | 20431 | 71826 | 29860119 |
Troponin I increased | 21.01 | 12.27 | 14 | 20519 | 1819 | 29930126 |
Anencephaly | 19.63 | 12.27 | 6 | 20527 | 118 | 29931827 |
Pericardial effusion | 19.37 | 12.27 | 44 | 20489 | 21100 | 29910845 |
Blood glucose decreased | 19.03 | 12.27 | 33 | 20500 | 13020 | 29918925 |
Cardiomegaly | 19.00 | 12.27 | 35 | 20498 | 14474 | 29917471 |
Blood creatinine increased | 18.81 | 12.27 | 117 | 20416 | 91258 | 29840687 |
Tracheal injury | 18.72 | 12.27 | 4 | 20529 | 16 | 29931929 |
Fluid overload | 17.79 | 12.27 | 40 | 20493 | 19052 | 29912893 |
Renal injury | 17.55 | 12.27 | 30 | 20503 | 11699 | 29920246 |
Peritonitis bacterial | 16.89 | 12.27 | 29 | 20504 | 11349 | 29920596 |
Hepatic function abnormal | 16.88 | 12.27 | 4 | 20529 | 41941 | 29890004 |
Hypocomplementaemia | 16.27 | 12.27 | 4 | 20529 | 33 | 29931912 |
Glomerulonephritis proliferative | 16.20 | 12.27 | 6 | 20527 | 216 | 29931729 |
Tubulointerstitial nephritis | 16.14 | 12.27 | 37 | 20496 | 17854 | 29914091 |
C-reactive protein increased | 15.89 | 12.27 | 5 | 20528 | 43468 | 29888477 |
Hyperparathyroidism secondary | 15.88 | 12.27 | 10 | 20523 | 1180 | 29930765 |
General physical health deterioration | 15.50 | 12.27 | 28 | 20505 | 99916 | 29832029 |
Cholestatic liver injury | 15.45 | 12.27 | 11 | 20522 | 1590 | 29930355 |
Bradycardia foetal | 15.30 | 12.27 | 6 | 20527 | 253 | 29931692 |
Neutropenia | 15.05 | 12.27 | 42 | 20491 | 128498 | 29803447 |
Renal impairment | 15.01 | 12.27 | 104 | 20429 | 84080 | 29847865 |
Hypertensive crisis | 14.71 | 12.27 | 23 | 20510 | 8334 | 29923611 |
Rheumatoid arthritis | 14.60 | 12.27 | 5 | 20528 | 41192 | 29890753 |
Rickets | 14.55 | 12.27 | 4 | 20529 | 53 | 29931892 |
Interstitial lung disease | 14.47 | 12.27 | 12 | 20521 | 60185 | 29871760 |
Asthenia | 13.97 | 12.27 | 221 | 20312 | 221069 | 29710876 |
Hyperkalaemia | 13.88 | 12.27 | 85 | 20448 | 65925 | 29866020 |
Nephrogenic systemic fibrosis | 13.80 | 12.27 | 16 | 20517 | 4355 | 29927590 |
Dialysis | 13.74 | 12.27 | 26 | 20507 | 10970 | 29920975 |
Acute febrile neutrophilic dermatosis | 13.73 | 12.27 | 9 | 20524 | 1137 | 29930808 |
Full blood count decreased | 13.62 | 12.27 | 32 | 20501 | 15685 | 29916260 |
Angioedema | 13.54 | 12.27 | 53 | 20480 | 34331 | 29897614 |
Vasculitis necrotising | 13.29 | 12.27 | 7 | 20526 | 590 | 29931355 |
Blood potassium increased | 12.97 | 12.27 | 32 | 20501 | 16181 | 29915764 |
Renal failure neonatal | 12.93 | 12.27 | 4 | 20529 | 82 | 29931863 |
Blood pressure inadequately controlled | 12.79 | 12.27 | 12 | 20521 | 2558 | 29929387 |
Gout | 12.62 | 12.27 | 33 | 20500 | 17282 | 29914663 |
Febrile neutropenia | 12.38 | 12.27 | 35 | 20498 | 106658 | 29825287 |
Chest pain | 12.31 | 12.27 | 129 | 20404 | 117498 | 29814447 |
Source | Code | Description |
---|---|---|
ATC | C02DB02 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON Hydrazinophthalazine derivatives |
ATC | C02LG02 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Hydrazinophthalazine derivatives and diuretics |
FDA PE | N0000175379 | Arteriolar Vasodilation |
FDA EPC | N0000175564 | Arteriolar Vasodilator |
CHEBI has role | CHEBI:35620 | vasodilator |
CHEBI has role | CHEBI:35674 | antihypertensive |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D014665 | Vasodilator Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Chronic heart failure | indication | 48447003 | |
Anuria | contraindication | 2472002 | DOID:2983 |
Suicidal thoughts | contraindication | 6471006 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Hypercholesterolemia | contraindication | 13644009 | |
Chronic disease of respiratory system | contraindication | 17097001 | |
Secondary angle-closure glaucoma | contraindication | 21571006 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Electroconvulsive therapy | contraindication | 23835007 | |
Hypovolemia | contraindication | 28560003 | |
Dehydration | contraindication | 34095006 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Depressive disorder | contraindication | 35489007 | |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Hypokalemia | contraindication | 43339004 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Low blood pressure | contraindication | 45007003 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Sympathectomy | contraindication | 57071006 | |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
Hypochloremic alkalosis | contraindication | 70134007 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Injury of head | contraindication | 82271004 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Hyponatremia | contraindication | 89627008 | |
Gout | contraindication | 90560007 | DOID:13189 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Increased intestinal motility | contraindication | 102624003 | |
Hypomagnesemia | contraindication | 190855004 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Cerebrovascular accident | contraindication | 230690007 | |
Hypertrophic cardiomyopathy | contraindication | 233873004 | DOID:11984 |
Lupus erythematosus and erythema multiforme-like syndrome | contraindication | 238926009 | |
Calculus in biliary tract | contraindication | 266474003 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Cerebral hemorrhage | contraindication | 274100004 | |
Neonatal hyperbilirubinemia | contraindication | 281610001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial infarction in recovery phase | contraindication | 418044006 | |
Slow acetylator due to N-acetyltransferase enzyme variant | contraindication | 425079005 | |
Azotemia | contraindication | 445009001 | |
Malabsorption States | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.81 | Basic |
pKa2 | 3.26 | Basic |
pKa3 | 2.62 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Ryanodine receptor 2 | Ion channel | BLOCKER | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
DNA (cytosine-5)-methyltransferase 3B | Enzyme | WOMBAT-PK | |||||||
DNA (cytosine-5)-methyltransferase 3A | Enzyme | WOMBAT-PK | |||||||
DNA (cytosine-5)-methyltransferase 1 | Enzyme | WOMBAT-PK | |||||||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | WOMBAT-PK | |||||||
Aldehyde oxidase | Enzyme | WOMBAT-PK | |||||||
Ryanodine receptor 2 | Ion channel | IC50 | 7.15 | SCIENTIFIC LITERATURE | |||||
Cholinesterase | Enzyme | Ki | 5.72 | CHEMBL | |||||
Acetylcholinesterase | Enzyme | Ki | 5.15 | CHEMBL | |||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.44 | DRUG MATRIX |
ID | Source |
---|---|
4019778 | VUID |
N0000147869 | NUI |
D01302 | KEGG_DRUG |
304-20-1 | SECONDARY_CAS_RN |
4017880 | VANDF |
4019778 | VANDF |
C0020223 | UMLSCUI |
CHEBI:5775 | CHEBI |
HLZ | PDB_CHEM_ID |
CHEMBL276832 | ChEMBL_ID |
CHEMBL542541 | ChEMBL_ID |
DB01275 | DRUGBANK_ID |
D006830 | MESH_DESCRIPTOR_UI |
7326 | IUPHAR_LIGAND_ID |
1 | INN_ID |
26NULLK24LS8 | UNII |
3637 | PUBCHEM_CID |
5470 | RXNORM |
4833 | MMSL |
896 | MMSL |
d00132 | MMSL |
000632 | NDDF |
004489 | NDDF |
22696000 | SNOMEDCT_US |
28662003 | SNOMEDCT_US |
387125005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-0901 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 19 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7973 | TABLET | 100 mg | ORAL | ANDA | 9 sections |
HydrALAZINE hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6231 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 18 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6440 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 8 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6441 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 8 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6442 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 8 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6443 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 8 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-934 | INJECTION | 20 mg | INTRAVENOUS | ANDA | 19 sections |
HYDRALAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-679 | TABLET | 10 mg | ORAL | ANDA | 11 sections |
HYDRALAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-680 | TABLET | 25 mg | ORAL | ANDA | 11 sections |
HYDRALAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-694 | TABLET | 50 mg | ORAL | ANDA | 11 sections |
HYDRALAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-695 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
HYDRALAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-001 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 8 sections |
HYDRALAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-002 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 8 sections |
HYDRALAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-003 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 8 sections |
HYDRALAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-004 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 8 sections |
BiDil | HUMAN PRESCRIPTION DRUG LABEL | 2 | 24338-010 | TABLET, FILM COATED | 37.50 mg | ORAL | NDA | 30 sections |
Hydralazine Hydrochloride | Human Prescription Drug Label | 1 | 31722-519 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Hydralazine Hydrochloride | Human Prescription Drug Label | 1 | 31722-520 | TABLET | 25 mg | ORAL | ANDA | 19 sections |
Hydralazine Hydrochloride | Human Prescription Drug Label | 1 | 31722-521 | TABLET | 50 mg | ORAL | ANDA | 19 sections |
Hydralazine Hydrochloride | Human Prescription Drug Label | 1 | 31722-522 | TABLET | 100 mg | ORAL | ANDA | 19 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35356-943 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0500 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 19 sections |
HYDRALAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-392 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 8 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-124 | TABLET | 100 mg | ORAL | ANDA | 18 sections |
HydrALAZINE Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-205 | TABLET | 100 mg | ORAL | ANDA | 12 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-742 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 20 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-756 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 20 sections |
Hydralazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-919 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 20 sections |
Hydralazine Hydrochloride | Human Prescription Drug Label | 1 | 50090-0137 | TABLET | 25 mg | ORAL | ANDA | 19 sections |